Disturbed EGFR signalling, due for example to the overexpression of EGFR, is involved in the pathogenesis of several cancer types, and antibodies directed towards the extracellular domain of EGFR have been developed for the treatment of cancers such as advanced colorectal cancer [13], [14]. The gene discussed is EGFR; the disease is colorectal cancer.